| EPC319 | Lactobacillus spp interaction with neat and formulated Griffithsin, a candidate for topical HIV prevention | E-poster | Other new HIV prevention tools |
| EPC320 | Identification of viral mutations that confer cross resistance to VRC01 antibody in HIV-1 subtype C viruses | E-poster | Other new HIV prevention tools |
| EPLBC04 | Transgender women (TGW) in HPTN 083: an evaluation of safety, efficacy, and gender affirming hormonal therapy (GAHT) interactions with long-acting cabotegravir (CAB-LA) | E-poster | Other new HIV prevention tools |
| EPLBC05 | Phase 3B, randomized, open-label, safety study of dapivirine vaginal ring and oral emtricitabine 200mg/tenofovir disoproxil fumarate 300 mg tablet in breastfeeding mother-infant pairs | E-poster | Other new HIV prevention tools |
| OALBX0107 | Long acting cabotegravir: updated efficacy and safety results from HPTN 084 | Oral abstract session with live Q&A | Other new HIV prevention tools |
| EPB099 | Epigenome-wide association study of liver function biomarkers identifies albumin-associated DNA methylation sites among male veterans with HIV | E-poster | Other non-communicable diseases |
| EPB100 | Women with HIV are at higher risk for obstructive lung disease in Kampala, Uganda after pulmonary tuberculosis | E-poster | Other non-communicable diseases |
| EPB101 | Increasing non-AIDS comorbidity burden among hospitalized persons with HIV (PWH) in the US and Canada | E-poster | Other non-communicable diseases |
| EPB102 | Factors associated with lower physical function among adults with HIV in the United States | E-poster | Other non-communicable diseases |
| EPB103 | Should HIV control programmes in Africa screen patients with HIV for multi-morbidity: findings from non-communicable diseases screening in the META trial in Dar es Salaam, Tanzania | E-poster | Other non-communicable diseases |